BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21804086)

  • 1. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
    Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL
    Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
    Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
    Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
    Yamaguchi T; Reif GA; Calvet JP; Wallace DP
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F944-51. PubMed ID: 20810616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
    Yamaguchi T; Nagao S; Wallace DP; Belibi FA; Cowley BD; Pelling JC; Grantham JJ
    Kidney Int; 2003 Jun; 63(6):1983-94. PubMed ID: 12753285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.
    Yuajit C; Muanprasat C; Gallagher AR; Fedeles SV; Kittayaruksakul S; Homvisasevongsa S; Somlo S; Chatsudthipong V
    Biochem Pharmacol; 2014 Apr; 88(3):412-21. PubMed ID: 24518257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
    Spirli C; Morell CM; Locatelli L; Okolicsanyi S; Ferrero C; Kim AK; Fabris L; Fiorotto R; Strazzabosco M
    Hepatology; 2012 Dec; 56(6):2363-74. PubMed ID: 22653837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis.
    He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B
    Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion.
    Nantavishit J; Chatsudthipong V; Soodvilai S
    Biochem Pharmacol; 2018 Aug; 154():175-182. PubMed ID: 29746821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease.
    Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP
    Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
    Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
    J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of DNA-Dependent Protein Kinase in Mediating Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.
    Chandra AN; Saravanabavan S; Rangan GK
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myofibroblast depletion reduces kidney cyst growth and fibrosis in autosomal dominant polycystic kidney disease.
    Dwivedi N; Jamadar A; Mathew S; Fields TA; Rao R
    Kidney Int; 2023 Jan; 103(1):144-155. PubMed ID: 36273656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
    Tonum K; Srimai N; Chabang N; Fongsupa S; Tuchinda P; Torres JA; Weimbs T; Soodvilai S
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat.
    Nagao S; Nishii K; Yoshihara D; Kurahashi H; Nagaoka K; Yamashita T; Takahashi H; Yamaguchi T; Calvet JP; Wallace DP
    Kidney Int; 2008 Feb; 73(3):269-77. PubMed ID: 17943077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model.
    Zhu Y; Teng T; Wang H; Guo H; Du L; Yang B; Yin X; Sun Y
    Food Funct; 2018 Jan; 9(1):389-396. PubMed ID: 29215110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients.
    Ikeda K; Kusaba T; Tomita A; Watanabe-Uehara N; Ida T; Kitani T; Yamashita N; Uehara M; Matoba S; Yamada T; Tamagaki K
    Nephron; 2020; 144(10):525-536. PubMed ID: 32799196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
    Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.